2-(4-甲脒基-2,3-二氢-1H-茚-1-基)肼羧酰胺 | 149400-88-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 2-(4-甲脒基-2,3-二氢-1H-茚-1-基)肼羧酰胺
• 英文名称: Sardomozide
• 英文别名: (1E)-1-(diaminomethylidenehydrazinylidene)-2,3-dihydroindene-4-carboximidamide
• CAS: 149400-88-4
• 化学式: C₁₁H₁₄N₆
• 分子量: 230.27
• InChiKey: CYPGNVSXMAUSJY-CXUHLZMHSA-N

物化性质

• 沸点：
  438.8±55.0 °C(Predicted)
• 密度：
  1.54±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  127
• 氢给体数：
  4
• 氢受体数：
  3

安全信息

• 海关编码：
  2928000090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

制备方法与用途

生物活性

Sardomozide 是一种 S-腺苷甲硫氨酸脱羧酶 (SAMDC) 抑制剂，其 IC50 值为 5 nM。

靶点

IC50: 5 nM (SAMDC)

体外研究

Sardomozide 是在细胞试验中表现出 S-腺苷甲硫氨酸脱羧酶 (SAMDC) 抑制活性的化合物，其 IC50 值为 5 nM。经过 48 小时，用 3 μM 的 Sardomozide 处理后，细胞内 SAMDC 活性降至对照组的 10%。在 CHO/664 细胞培养过程中添加 Sardomozide 并随后使用 DENSPM 处理时，并未观察到溶酶体形成，且这些细胞表现出生长抑制并含有与亲代CHO细胞相似水平的DENSPM。

反应信息

• 作为产物：
  描述：

  1-氧亚基-2,3-二氢-1H-茚-4-甲脒 、 氨基胍碳酸氢盐 在 氨基胍碳酸氢盐 作用下， 以72的产率得到2-(4-甲脒基-2,3-二氢-1H-茚-1-基)肼羧酰胺
  参考文献：
  名称：

  J. Med. Chem. 1993, 36, 2168-2171

  摘要：

  DOI：

文献信息

• Polyamine-metal chelator conjugates
  申请人：Bergeron J. Raymond

  公开号：US20060211773A1

  公开（公告）日：2006-09-21

  Many metal collators have polar or charged functional groups, which render them difficult to transport across a cell membrane. Polyimide-metal collator conjugates of the invention are compounds comprising a first moiety which is a metal collator and a second moiety which is a polyimide, where the polyimide moiety includes three or more nitrogen atoms which are capable of being positively charged at physiological pH. A sperms-L1 conjugate has been shown to accumulate in L1210 cells several hundred fold more than the unconjugated L1 chelator.

  许多金属配体具有极性或带电的功能基团，这使它们难以穿过细胞膜。本发明的聚酰亚胺-金属配体共轭物是由第一部分为金属配体，第二部分为聚酰亚胺的化合物组成，其中聚酰亚胺部分包含三个或更多的氮原子，在生理pH下能够呈正电荷。已经证明，精子-L1共轭物在L1210细胞中的积累量比未共轭的L1螯合剂高出数百倍。
• Polyamine-Metal Chelator Conjugates
  申请人：Bergeron Raymond

  公开号：US20080096974A2

  公开（公告）日：2008-04-24

  Many metal chelators have polar or charged functional groups, which render them difficult to transport across a cell membrane. Polyamine-metal chelator conjugates of the invention are compounds comprising a first moiety which is a metal chelator and a second moiety which is a polyamine, where the polyamine moiety includes three or more nitrogen atoms which are capable of being positively charged at physiological pH. A spermine-L1 conjugate has been shown to accumulate in L1210 cells several hundred fold more than the unconjugated L1 chelator.

  许多金属螯合剂具有极性或带电的功能基团，这使得它们难以跨越细胞膜。本发明的多胺-金属螯合剂共轭物是化合物，包括第一部分是金属螯合剂，第二部分是多胺，其中多胺部分包括三个或更多的氮原子，在生理pH下能够呈正电荷。已经证明精胺-L1共轭物在L1210细胞中的积累比未共轭的L1螯合剂高出数百倍。
• ANTI-CANCER PHOSPHONATE ANALOGS
  申请人：Boojamra Constantine G.

  公开号：US20100022467A1

  公开（公告）日：2010-01-28

  The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.

  本发明涉及磷取代的抗癌化合物、含有这些化合物的组合物以及包括给予这些化合物的治疗方法，还涉及用于制备这些化合物的过程和中间体。
• 5',-SUBSTITUTED ADENOSYNES PREPARATION THEREOF AND USE AS INHIBITORS OF S-ADENOSYLMETHIONINE DECARBOXYLASE
  申请人：Secrist, III John A.

  公开号：US20110009354A1

  公开（公告）日：2011-01-13

  The crystal structure of the complex of S-adenosylmethionine methyl ester with hΛdoMetDC F223A, a mutant where the stacking of the aromatic rings of F7, adenine and F223 would be eliminated. The structure of this mutant with the ester shows that the ligand still maintains a syn conformation aided by pi-pi interactions to F7, hydrogen bonds to the backbone of Glu67, and electrostatic interactions. Several series of AdoMet substrate analogues with a variety of substituents at the 8 position of adenine were synthesized and analyzed for their ability to inhibit hAdoMetDC. To understand these results, virtual modeling of the enzyme inhibitor complexes and the crystal structures of human AdoMetDC with 5′-deoxy-5′-[N-methyl-N-[2-(aminooxy)ethyl]amino-8-methyl]adenosine (MAOEMA) and 5′-deoxy-5′-[N-methyl-N-[4-(aminooxy)butyl]amino-8-ethyl]adenosine (MAOBEA) at the active site have been determined experimentally.

  S-腺苷甲硫氨酸甲酯与hΛdoMetDC F223A复合物的晶体结构已被确定，该突变体中F7、腺嘌呤和F223的芳香环堆叠被消除。该突变体与酯的结构表明，配体仍通过与F7的π-π相互作用、与Glu67骨架的氢键和静电相互作用来维持同构构象。合成了几个AdoMet底物类似物系列，这些类似物在腺嘌呤的8位具有不同的取代基，分析它们抑制hAdoMetDC的能力。为了理解这些结果，通过虚拟建模酶抑制剂复合物和人类AdoMetDC与5'-去氧-5'-[N-甲基-N-[2-(氨氧)乙基]氨基-8-甲基]腺苷(MAOEMA)和5'-去氧-5'-[N-甲基-N-[4-(氨氧)丁基]氨基-8-乙基]腺苷(MAOBEA)在活性位点的晶体结构已被实验确定。
• Use of specific hydrazone compounds for the treatment of viral infections
  申请人：Heinrich-Pette-Institut

  公开号：EP1834669A1

  公开（公告）日：2007-09-19

  The present invention relates to the use of specific hydrazone compounds for the treatment of viral infections, in particular of retroviral infections and most preferably of lentiviral or oncoretroviral infections. According to a specific embodiment of the invention, the compound is 2-[4-(aminoiminomethyl)-2,3-dihydro-1H-inden-1-ylidene]-hydrazinecarboximidamide or a salt thereof, and the retroviral infection is an HIV infection, in particular HIV-1.

  本发明涉及使用特定的腙化合物治疗病毒感染，特别是逆转录病毒感染，最优选的是慢病毒或逆转录病毒感染。根据本发明的一个具体实施例，该化合物是 2-[4-(氨基亚氨基甲基)-2,3-二氢-1H-茚-1-亚基]-肼甲脒或其盐，逆转录病毒感染是 HIV 感染，特别是 HIV-1。